Supplying the newest API's & rarest Molecules for your R&D needsSupplying the newest API's & rarest Molecules for your R&D needs
Home Products Company Profile Compounding Products Events Resources Blog Contact Us

Latest News


LGM Pharma Showcased by Palm Beach County's Business Development Board

VilazodoneLGM Pharma was invited to participate in an industry spotlight during the recent Life Sciences Industry Focus Luncheon by the Business Development Board on November 8, 2011 in Palm Beach County.

The invitation, which was issued to a select number of Palm Beach County life sciences companies, was intended to showcase new and innovative life sciences companies that have started or moved to Palm Beach County since the Scripps relocation. This showcase demonstrated to the business community and elected officials in Palm Beach County the return on the investment from establishing and building a life sciences cluster in Palm Beach County.

Read More >


Drug Development Boot Camp Holds True to its Name

DocetaxelRobert Hoppes, Director of Sales for R&D for LGM Pharma, recently attended the Drug Development Boot Camp offered by Speid & Associates, Inc. and Harvard University's Office of Technology Development.

This intensive two-day course for Biotech and Pharma company executives provided an opportunity for participants to obtain a hands-on insight into the drug development process from drug discovery to regulatory approval. The program presented a unique interactive platform to engage with industry colleagues from a variety of disciplines on each step of the drug development process. The drug development boot camp also presented a good forum to discuss the changing landscape of the pharmaceutical industry. Much of the dialogue was about the shift to specialization rather than having all aspects of the development process done in-house by one company. With all of the downsizing and constricting of drug pipelines, more emphasis is being placed on outsourcing expertise and increasing collaboration..

Read More >


LGM Pharma Receives Certification from the International Organization for Standardization

DocetaxelLGM Pharma has received certification from the International Organization for Standardization (ISO), a group that addresses quality management. Click here to view the ISO 9001:2008 certificate.

ISO 9001:2008 is the benchmark that provides a set of standardized requirements for a quality management system, regardless of what the user organization does, its size, or whether it is in the private, or public sector. It is the only standard against which organizations can be certified.

The standards are about assisting organizations to achieve customer satisfaction. As customer needs and expectations are changing, the effective organizations are driven to continually improve their products, services and processes.

According to Robert Hoppes, Director of Sales for R&D, "LGM Pharma is committed to our clients' success by providing rare and novel active pharmaceutical ingredients of the highest quality for their drug development and research projects. Our goal is to exceed our clients' expectations by ensuring our products' quality is consistently of the highest standards, ensure on-time delivery, provide technical and regulatory assistance and empower our employees to promote continuous improvement of our systems.".

Read More >

Recent Blog Posts

Delivering a safe supply of active pharmaceutical ingredients to developing countries
Posted on: 11/16/11

vaccination in developing countries As is the case in almost every industry, pharmaceutical manufacturing is becoming an increasingly global business. Between 2001 and 2008, the number of drugs produced outside the U.S. doubled. While this certainly reduces production costs for manufacturers and potentially reduces the costs that consumers pay for pharmaceuticals, the safety of the drugs may be sacrificed in the process. When the manufacturers outsource their production, the level of actual control for both the manufacturer and the Food and Drug Administration (FDA) is effectively reduced... More >




Ancrod present favorable benefit-risk outcomes in ischemic stroke patients
Posted on: 11/4/11

ischemic stroke pathophysiologyA randomized controlled study done by David G. Sherman et al. in community hospitals across the US and Canada found favorable outcomes in ischemic stroke patients being treated with Ancrod within 3 hours of the onset compared to those who were on placebo. Mortality rates were not significantly different between the two groups but the functional disability of those patients on placebo was higher than those treated with Ancrod. These results proved that Ancrod presents improved clinical outcomes for ischemic stroke patients...
More >



Recent Videos

LGM Pharma - Active Pharmaceutical Ingredient Supplier

LGM Pharma video thumb



Disclaimer: Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.



Facebook IconTwitter IconLinkedIn IconYouTube Icon
Address: 3200 West End Ave, Suite 500, Nashville, TN 37203 • Phone: 1-(800)-881-8210 • Fax: 1-615-250-9817
Copyright © 2012 LGM Pharma. All Rights Reserved | Privacy Policy | Sitemap